Hematology Research
Researchers in the Division of Hematology work to discover and provide advanced treatments for children and adolescents with blood disorders. Our goal is to develop better treatments for conditions including hemophilia, sickle cell disease, thrombosis, vascular malformations and many others.
We’ve been researching blood disorders since 1920. Our strong history strengthens today’s collaborative work in basic, clinical and translational studies. Our faculty lead more than 20 research programs at Cincinnati Children’s. We collaborate with experts in many other divisions at Cincinnati Children's, as well as federal agencies, national organizations, and experts in other countries.
The hematology division is part of Cincinnati Children’s Cancer and Blood Diseases Institute. We advance care through a wide range of programs. Our faculty lead clinical research activities supported by the Clinical Management and Research Support Core.
Our Research
We study a full spectrum of conditions—and many ways to prevent, treat and potentially cure them. Our faculty-led research teams include hematologists and researchers, as well as care managers, child life specialists, data managers, laboratory associates, nurse practitioners, PhD psychologists, school intervention coordinators and social workers, among others.
Conditions and disorders we study include:
- Erythropoiesis and red cell biology
- Hemangiomas
- Hemophilia and Bleeding Disorders
- Pediatric thrombosis
- Sickle cell disease
- Vascular anomalies
Our research involves:
- Determining the best treatments for sickle cell disease
- Evaluating risk of thrombosis with hormonal therapy
- Investigating new treatments for hemophilia
- Investigating the biomarkers, natural history and rare presentations of vascular anomalies
- Medical treatments for vascular anomalies
- Targeted therapies and precision dosing
Hematology faculty have made discoveries that are providing new opportunities for potential treatments. Examples include:
- Erythrocyte cytoskeleton organization. By highlighting these signaling proteins we offer potential new targets for treating hemolytic anemias.
- Creation of the CDA Registry of North America. Congenital dyserythropoietic anemias (CDA) are a group of rare anemias characterized by ineffective erythropoiesis and hemolysis. We developed the registry to improve understanding of the natural history of the disease, facilitate early diagnosis, understand the molecular defects and pathogenetic mechanisms in CDA, and optimize management of this heterogeneous group of rare diseases. Through this registry we identified novel genes associated with CDA and human erythropoiesis.
On a national level, our Hematology Research teams participate in the Center for Disease Control and Prevention’s long-standing surveillance project on bleeding disorders and in several American Thrombosis and Hemostasis Network studies.
